Tirzepatide is the first dual glucose-dependent insulinotropic polypeptide (GIP)/GLP- 1 receptor co-agonist approved for the treatment of T2DM in the USA, Europe, and the United Arab Emirates [4]
These findings are the results of several clinical studies which you will find in the Experimental Phytotherapy paragraph
These medications can make you feel full sooner, which may also mean you drink less without realizing it
For the full breakdown of how that combination works and why the two peptides are synergistic, the complete Wolverine stack guide at Perfect B explains the BPC-157 and TB-500 combination protocol, the 3-phase healing timeline, and what patients in South Florida typically see from the combined approach
With the last expiring follow-on patent being in 2042, this amounts to a period of 49 years of patent protection in total
in the intestine through niche competition (Ji et al., 2023)